Evaluation of platelet function in MPNs (MPN-PLATE)
Research type
Research Study
Full title
Platelet function testing using multiple electrode aggregometry in patients with myeloproliferative neoplasms on antiplatelet medications.
IRAS ID
234430
Contact name
Hafiz Qureshi
Contact email
Sponsor organisation
University Hospitals of Leicester
Duration of Study in the UK
2 years, 0 months, 5 days
Research summary
The myeloproliferative neoplasms (MPN) Essential Thrombocythaemia (ET), Polycythaemia Vera (PRV) and Primary Myelofibrosis (PMF), are associated with an increased risk of thrombosis which is multi-factorial. Antiplatelet therapy has been shown to reduce the risk of thromboembolic disease in PRV and is therefore prescribed for all patients with MPN. However, experience from antiplatelet use in cardiovascular disease reveals a significant group of patients (around 15%) who are non-responsive to the antiplatelet drugs both clinically and in laboratory testing. The incidence and implications of aspirin non-response has not been widely studied in MPN. We propose a study investigating platelet function in patients with MPN on antiplatelet therapy, using multiple electrode aggregometry; using whole blood sample. We aim to perform platelet function tests at regular intervals to assess the incidence of aspirin non-response in MPN. Furthermore, the study aims to determine if non-response to aspirin and other anti-platelet drugs correlates with the incidence of thrombotic events.
REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
18/EM/0396
Date of REC Opinion
19 Dec 2018
REC opinion
Favourable Opinion